Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 42 entries
Sorted by: Best Match Show Resources per page
Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor associated cutaneous adverse drug reactions: A systematic review of case reports and case series.

The Australasian journal of dermatology

Masuka JT, Mchunu N, Mkhize Z, Thandar Y, Mosam A.
PMID: 34958129
Australas J Dermatol. 2021 Dec 27; doi: 10.1111/ajd.13780. Epub 2021 Dec 27.

Anecdotal evidence suggests that selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) cause cutaneous adverse drug reactions (CADRs). However, there is limited information on the factors associated with these occurrences. In this study, we aimed...

Cite
Masuka JT, Mchunu N, Mkhize Z, et al. Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor associated cutaneous adverse drug reactions: A systematic review of case reports and case series. Australas J Dermatol. 2021;doi: 10.1111/ajd.13780.
Masuka, J. T., Mchunu, N., Mkhize, Z., Thandar, Y., & Mosam, A. (2021). Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor associated cutaneous adverse drug reactions: A systematic review of case reports and case series. The Australasian journal of dermatology, . https://doi.org/10.1111/ajd.13780
Masuka, Josiah T, et al. "Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor associated cutaneous adverse drug reactions: A systematic review of case reports and case series." The Australasian journal of dermatology vol. (2021). doi: https://doi.org/10.1111/ajd.13780
Masuka JT, Mchunu N, Mkhize Z, Thandar Y, Mosam A. Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor associated cutaneous adverse drug reactions: A systematic review of case reports and case series. Australas J Dermatol. 2021 Dec 27; doi: 10.1111/ajd.13780. Epub 2021 Dec 27. PMID: 34958129.
Copy Download .nbib Format: NLM
Rapid response to selective serotonin reuptake inhibitors in post-COVID depression.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F.
PMID: 34634679
Eur Neuropsychopharmacol. 2021 Oct 08;54:1-6. doi: 10.1016/j.euroneuro.2021.09.009. Epub 2021 Oct 08.

The spreading of the Severe Acute Respiratory Syndrome Coronavirus (COVID-19) pandemic could be associated with psychiatric implications. After COVID-19, depression was reported in 40% of patients at one-, three-, and six-months follow-up. Emerging literature suggests anti-inflammatory and antiviral properties...

Cite
Mazza MG, Zanardi R, Palladini M, et al. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol. 2021;54:1-6doi: 10.1016/j.euroneuro.2021.09.009.
Mazza, M. G., Zanardi, R., Palladini, M., Rovere-Querini, P., & Benedetti, F. (2021). Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 541-6. https://doi.org/10.1016/j.euroneuro.2021.09.009
Mazza, Mario Gennaro, et al. "Rapid response to selective serotonin reuptake inhibitors in post-COVID depression." European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology vol. 54 (2021): 1-6. doi: https://doi.org/10.1016/j.euroneuro.2021.09.009
Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol. 2021 Oct 08;54:1-6. doi: 10.1016/j.euroneuro.2021.09.009. Epub 2021 Oct 08. PMID: 34634679; PMCID: PMC8500775.
Copy Download .nbib Format: NLM
Serotonin Syndrome With Fluoxetine: Two Case Reports.

The Ochsner journal

Patel DD, Galarneau D.
PMID: 27999518
Ochsner J. 2016;16(4):554-557.

BACKGROUND: Serotonin syndrome is a rare but serious complication of treatment with serotonergic agents. In its severe manifestations, death can ensue. Early recognition and aggressive management are crucial to mitigating the syndrome. Often the presentation can be subtle and...

Cite
Patel DD, Galarneau D. Serotonin Syndrome With Fluoxetine: Two Case Reports. Ochsner J. 2016;16(4):554-557
Patel, D. D., & Galarneau, D. (2016). Serotonin Syndrome With Fluoxetine: Two Case Reports. The Ochsner journal, 16(4), 554-557.
Patel, Dipen Dineshkumar, and Galarneau, David. "Serotonin Syndrome With Fluoxetine: Two Case Reports." The Ochsner journal vol. 16,4 (2016): 554-557.
Patel DD, Galarneau D. Serotonin Syndrome With Fluoxetine: Two Case Reports. Ochsner J. 2016;16(4):554-557. PMID: 27999518; PMCID: PMC5158166.
Copy Download .nbib Format: NLM
Fluoxetine Does Not Enhance Visual Perceptual Learning and Triazolam Specifically Impairs Learning Transfer.

Frontiers in human neuroscience

Lagas AK, Black JM, Byblow WD, Fleming MK, Goodman LK, Kydd RR, Russell BR, Stinear CM, Thompson B.
PMID: 27807412
Front Hum Neurosci. 2016 Oct 19;10:532. doi: 10.3389/fnhum.2016.00532. eCollection 2016.

The selective serotonin reuptake inhibitor fluoxetine significantly enhances adult visual cortex plasticity within the rat. This effect is related to decreased gamma-aminobutyric acid (GABA) mediated inhibition and identifies fluoxetine as a potential agent for enhancing plasticity in the adult...

Cite
Lagas AK, Black JM, Byblow WD, et al. Fluoxetine Does Not Enhance Visual Perceptual Learning and Triazolam Specifically Impairs Learning Transfer. Front Hum Neurosci. 2016;10:532doi: 10.3389/fnhum.2016.00532.
Lagas, A. K., Black, J. M., Byblow, W. D., Fleming, M. K., Goodman, L. K., Kydd, R. R., Russell, B. R., Stinear, C. M., & Thompson, B. (2016). Fluoxetine Does Not Enhance Visual Perceptual Learning and Triazolam Specifically Impairs Learning Transfer. Frontiers in human neuroscience, 10532. https://doi.org/10.3389/fnhum.2016.00532
Lagas, Alice K, et al. "Fluoxetine Does Not Enhance Visual Perceptual Learning and Triazolam Specifically Impairs Learning Transfer." Frontiers in human neuroscience vol. 10 (2016): 532. doi: https://doi.org/10.3389/fnhum.2016.00532
Lagas AK, Black JM, Byblow WD, Fleming MK, Goodman LK, Kydd RR, Russell BR, Stinear CM, Thompson B. Fluoxetine Does Not Enhance Visual Perceptual Learning and Triazolam Specifically Impairs Learning Transfer. Front Hum Neurosci. 2016 Oct 19;10:532. doi: 10.3389/fnhum.2016.00532. eCollection 2016. PMID: 27807412; PMCID: PMC5069436.
Copy Download .nbib Format: NLM
The Diagnostic Role of Neurophysiological Tests for Premature Ejaculation: A Prospective Multicenter Study.

The Journal of urology

Yang B, Hong Z, Luse DC, Han Y, Sun G, Feng Y, Zhang C, Sun C, Xu Z, Chen H, Yao B, Liu K, Zhu W, Chen Y, Wang R, Dai Y, Xia J.
PMID: 34455861
J Urol. 2022 Jan;207(1):172-182. doi: 10.1097/JU.0000000000002198. Epub 2021 Aug 30.

PURPOSE: Premature ejaculation (PE) is one of the most common male sexual dysfunctions. Local anesthetics (LAs) and dapoxetine are frequently used to treat PE; however, previous studies show variable efficacy. This study aims to determine the efficacy of LAs...

Cite
Yang B, Hong Z, Luse DC, et al. The Diagnostic Role of Neurophysiological Tests for Premature Ejaculation: A Prospective Multicenter Study. J Urol. 2021;207(1):172-182doi: 10.1097/JU.0000000000002198.
Yang, B., Hong, Z., Luse, D. C., Han, Y., Sun, G., Feng, Y., Zhang, C., Sun, C., Xu, Z., Chen, H., Yao, B., Liu, K., Zhu, W., Chen, Y., Wang, R., Dai, Y., & Xia, J. (2022). The Diagnostic Role of Neurophysiological Tests for Premature Ejaculation: A Prospective Multicenter Study. The Journal of urology, 207(1), 172-182. https://doi.org/10.1097/JU.0000000000002198
Yang, Baibing, et al. "The Diagnostic Role of Neurophysiological Tests for Premature Ejaculation: A Prospective Multicenter Study." The Journal of urology vol. 207,1 (2022): 172-182. doi: https://doi.org/10.1097/JU.0000000000002198
Yang B, Hong Z, Luse DC, Han Y, Sun G, Feng Y, Zhang C, Sun C, Xu Z, Chen H, Yao B, Liu K, Zhu W, Chen Y, Wang R, Dai Y, Xia J. The Diagnostic Role of Neurophysiological Tests for Premature Ejaculation: A Prospective Multicenter Study. J Urol. 2022 Jan;207(1):172-182. doi: 10.1097/JU.0000000000002198. Epub 2021 Aug 30. PMID: 34455861; PMCID: PMC8667790.
Copy Download .nbib Format: NLM
Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis.

Stroke

Jones JS, Kimata R, Almeida OP, Hankey GJ.
PMID: 34167325
Stroke. 2021 Aug;52(9):2802-2808. doi: 10.1161/STROKEAHA.120.032973. Epub 2021 Jun 25.

BACKGROUND AND PURPOSE: Stroke survivors have an increased risk of depression and bone fractures. Selective serotonin reuptake inhibitors (SSRIs) have been associated with an increased risk of fractures in observational studies. Several randomized controlled trials (RCTs) reporting the effect...

Cite
Jones JS, Kimata R, Almeida OP, et al. Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. Stroke. 2021;52(9):2802-2808doi: 10.1161/STROKEAHA.120.032973.
Jones, J. S., Kimata, R., Almeida, O. P., & Hankey, G. J. (2021). Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. Stroke, 52(9), 2802-2808. https://doi.org/10.1161/STROKEAHA.120.032973
Jones, Joshua S, et al. "Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis." Stroke vol. 52,9 (2021): 2802-2808. doi: https://doi.org/10.1161/STROKEAHA.120.032973
Jones JS, Kimata R, Almeida OP, Hankey GJ. Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. Stroke. 2021 Aug;52(9):2802-2808. doi: 10.1161/STROKEAHA.120.032973. Epub 2021 Jun 25. PMID: 34167325.
Copy Download .nbib Format: NLM
Rapid response to selective serotonin reuptake inhibitors in post-COVID depression.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F.
PMID: 34634679
Eur Neuropsychopharmacol. 2022 Jan;54:1-6. doi: 10.1016/j.euroneuro.2021.09.009. Epub 2021 Oct 09.

The spreading of the Severe Acute Respiratory Syndrome Coronavirus (COVID-19) pandemic could be associated with psychiatric implications. After COVID-19, depression was reported in 40% of patients at one-, three-, and six-months follow-up. Emerging literature suggests anti-inflammatory and antiviral properties...

Cite
Mazza MG, Zanardi R, Palladini M, et al. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol. 2021;54:1-6doi: 10.1016/j.euroneuro.2021.09.009.
Mazza, M. G., Zanardi, R., Palladini, M., Rovere-Querini, P., & Benedetti, F. (2022). Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 541-6. https://doi.org/10.1016/j.euroneuro.2021.09.009
Mazza, Mario Gennaro, et al. "Rapid response to selective serotonin reuptake inhibitors in post-COVID depression." European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology vol. 54 (2022): 1-6. doi: https://doi.org/10.1016/j.euroneuro.2021.09.009
Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol. 2022 Jan;54:1-6. doi: 10.1016/j.euroneuro.2021.09.009. Epub 2021 Oct 09. PMID: 34634679; PMCID: PMC8500775.
Copy Download .nbib Format: NLM
Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis.

Stroke

Jones JS, Kimata R, Almeida OP, Hankey GJ.
PMID: 34167325
Stroke. 2021 Aug;52(9):2802-2808. doi: 10.1161/STROKEAHA.120.032973. Epub 2021 Jun 25.

[Figure: see text].

Cite
Jones JS, Kimata R, Almeida OP, et al. Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. Stroke. 2021;52(9):2802-2808doi: 10.1161/STROKEAHA.120.032973.
Jones, J. S., Kimata, R., Almeida, O. P., & Hankey, G. J. (2021). Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. Stroke, 52(9), 2802-2808. https://doi.org/10.1161/STROKEAHA.120.032973
Jones, Joshua S, et al. "Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis." Stroke vol. 52,9 (2021): 2802-2808. doi: https://doi.org/10.1161/STROKEAHA.120.032973
Jones JS, Kimata R, Almeida OP, Hankey GJ. Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. Stroke. 2021 Aug;52(9):2802-2808. doi: 10.1161/STROKEAHA.120.032973. Epub 2021 Jun 25. PMID: 34167325.
Copy Download .nbib Format: NLM
Drug-Resistant Hyponatremia after Escitalopram Intake: A Series of Two Case Reports.

Annals of geriatric medicine and research

Kacperczyk J, Perdyan A, Stompór M.
PMID: 34610667
Ann Geriatr Med Res. 2021 Sep;25(3):217-221. doi: 10.4235/agmr.21.0062. Epub 2021 Sep 29.

The consumption of new selective serotonin reuptake inhibitors (SSRIs) is raising dramatically especially in European countries. It contributes to occurrence of clinically important drug side effects. One of which can be hyponatremia. We present two case reports of 85-year-old...

Cite
Kacperczyk J, Perdyan A, Stompór M. Drug-Resistant Hyponatremia after Escitalopram Intake: A Series of Two Case Reports. Ann Geriatr Med Res. 2021;25(3):217-221doi: 10.4235/agmr.21.0062.
Kacperczyk, J., Perdyan, A., & Stompór, M. (2021). Drug-Resistant Hyponatremia after Escitalopram Intake: A Series of Two Case Reports. Annals of geriatric medicine and research, 25(3), 217-221. https://doi.org/10.4235/agmr.21.0062
Kacperczyk, Justyna, et al. "Drug-Resistant Hyponatremia after Escitalopram Intake: A Series of Two Case Reports." Annals of geriatric medicine and research vol. 25,3 (2021): 217-221. doi: https://doi.org/10.4235/agmr.21.0062
Kacperczyk J, Perdyan A, Stompór M. Drug-Resistant Hyponatremia after Escitalopram Intake: A Series of Two Case Reports. Ann Geriatr Med Res. 2021 Sep;25(3):217-221. doi: 10.4235/agmr.21.0062. Epub 2021 Sep 29. PMID: 34610667; PMCID: PMC8497947.
Copy Download .nbib Format: NLM
Effects of long-term treatment of rats with antidepressants on adrenergic-receptor sensitivity in cerebral cortex: Structure activity study.

Neurochemistry international

Kopanski C, Türck M, Schultz JE.
PMID: 20487994
Neurochem Int. 1983;5(5):649-59. doi: 10.1016/0197-0186(83)90059-1.

The effects of 20 tricyclic and 12 chemically unrelated 'atypical' antidepressant drugs on the noradrenaline (NA) receptor coupled adenylate cyclase system were investigated in slices of the rat cerebral cortex. While no changes occurred after a single dose, 14...

Cite
Kopanski C, Türck M, Schultz JE. Effects of long-term treatment of rats with antidepressants on adrenergic-receptor sensitivity in cerebral cortex: Structure activity study. Neurochem Int. 1983;5(5):649-59doi: 10.1016/0197-0186(83)90059-1.
Kopanski, C., Türck, M., & Schultz, J. E. (1983). Effects of long-term treatment of rats with antidepressants on adrenergic-receptor sensitivity in cerebral cortex: Structure activity study. Neurochemistry international, 5(5), 649-59. https://doi.org/10.1016/0197-0186(83)90059-1
Kopanski, C, et al. "Effects of long-term treatment of rats with antidepressants on adrenergic-receptor sensitivity in cerebral cortex: Structure activity study." Neurochemistry international vol. 5,5 (1983): 649-59. doi: https://doi.org/10.1016/0197-0186(83)90059-1
Kopanski C, Türck M, Schultz JE. Effects of long-term treatment of rats with antidepressants on adrenergic-receptor sensitivity in cerebral cortex: Structure activity study. Neurochem Int. 1983;5(5):649-59. doi: 10.1016/0197-0186(83)90059-1. PMID: 20487994.
Copy Download .nbib Format: NLM
Intra-arterial Chemotherapy with Carboplatin (CBDCA) and Vepesid (VP16) in Primary Malignant Brain Tumours. Preliminary Findings.

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences

Clocchlatti L, Cartei G, Lavaroni A, Vigevani E, Fabrls G, Tommasini G, Leonardi M.
PMID: 20682108
Interv Neuroradiol. 1996 Dec 20;2(4):277-81. doi: 10.1177/159101999600200405. Epub 2001 May 15.

SUMMARY: Twenty three patients (18 males) were followed from January 1993 to July 1996 for primary central nervous system malignancy: glioblastoma multiforme (GM) (15 patients), anaplastic astrocytoma (AA) (8 patients). Ninety one cycles (average 4 cycles per patient) of...

Cite
Clocchlatti L, Cartei G, Lavaroni A, et al. Intra-arterial Chemotherapy with Carboplatin (CBDCA) and Vepesid (VP16) in Primary Malignant Brain Tumours. Preliminary Findings. Interv Neuroradiol. 2001;2(4):277-81doi: 10.1177/159101999600200405.
Clocchlatti, L., Cartei, G., Lavaroni, A., Vigevani, E., Fabrls, G., Tommasini, G., & Leonardi, M. (1996). Intra-arterial Chemotherapy with Carboplatin (CBDCA) and Vepesid (VP16) in Primary Malignant Brain Tumours. Preliminary Findings. Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2(4), 277-81. https://doi.org/10.1177/159101999600200405
Clocchlatti, L, et al. "Intra-arterial Chemotherapy with Carboplatin (CBDCA) and Vepesid (VP16) in Primary Malignant Brain Tumours. Preliminary Findings." Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences vol. 2,4 (1996): 277-81. doi: https://doi.org/10.1177/159101999600200405
Clocchlatti L, Cartei G, Lavaroni A, Vigevani E, Fabrls G, Tommasini G, Leonardi M. Intra-arterial Chemotherapy with Carboplatin (CBDCA) and Vepesid (VP16) in Primary Malignant Brain Tumours. Preliminary Findings. Interv Neuroradiol. 1996 Dec 20;2(4):277-81. doi: 10.1177/159101999600200405. Epub 2001 May 15. PMID: 20682108.
Copy Download .nbib Format: NLM
Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.

Neuropsychiatric disease and treatment

Chow TW, Pollock BG, Milgram NW.
PMID: 19300592
Neuropsychiatr Dis Treat. 2007;3(5):627-36.

OBJECTIVE: Selective serotonin reuptake inhibitors (SSRIs) have increased cognitive performance in some clinical studies of Alzheimer's disease (AD), but it is has been difficult to dissociate whether this is due to direct effects on cognition (neurochemical or disease-modifying) or...

Cite
Chow TW, Pollock BG, Milgram NW. Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. Neuropsychiatr Dis Treat. 2007;3(5):627-36
Chow, T. W., Pollock, B. G., & Milgram, N. W. (2007). Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. Neuropsychiatric disease and treatment, 3(5), 627-36.
Chow, Tiffany W, et al. "Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease." Neuropsychiatric disease and treatment vol. 3,5 (2007): 627-36.
Chow TW, Pollock BG, Milgram NW. Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. Neuropsychiatr Dis Treat. 2007;3(5):627-36. PMID: 19300592; PMCID: PMC2656299.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 42 entries